Brad Pruitt is Director of Oncology and Urology Marketing at Medivation, Inc. He has spent over 20 years in the biotechnology / pharmaceutical industry, with a career that includes progressive leadership roles at Eli Lilly and Company, Amgen, and Medivation. For the last 9 years, he has specialized in the commercialization of therapeutic and supportive care products in oncology and hematology. Brad has led cross-functional teams consisting of research and development, clinical, medical affairs, regulatory, manufacturing and commercialization colleagues through global Phase 1 and 2 drug development. He has also led commercialization teams through phase 3 product launch planning and FDA approval for 5 products. Two of these products were focused in the oncology/hematology therapeutic area including a product which was granted priority review by FDA through its orphan drug status designation. He was trained as a pharmacist and currently resides in San Francisco. Brad is committed to using his industry knowledge and experience to aid SFA’s fight to eliminate the pain and suffering caused by sarcoma – a vital goal that became deeply personal after the loss of a dear friend to the disease.